Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole
<p>Abstract</p> <p>Background</p> <p>AIDS-associated cryptococcal meningitis has a high mortality. Fluconazole was the only systemic antifungal therapy available in our centre. From 1999–2001 we used low-dose fluconazole (200 mg daily initially), and did not offer thera...
Main Authors: | Morroni C, Meintjes GA, Schaars CF, Post FA, Maartens G |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2006-07-01
|
Series: | BMC Infectious Diseases |
Online Access: | http://www.biomedcentral.com/1471-2334/6/118 |
Similar Items
-
Emerging fluconazole resistance: Implications for the management of cryptococcal meningitis
by: Edward Mpoza, et al.
Published: (2018-03-01) -
A prospective study of mortality from cryptococcal meningitis following treatment induction with 1200 mg oral fluconazole in Blantyre, Malawi.
by: Katherine M Gaskell, et al.
Published: (2014-01-01) -
High dose fluconazole in salvage therapy for HIV-uninfected cryptococcal meningitis
by: Hua-Zhen Zhao, et al.
Published: (2018-12-01) -
A prospective longitudinal study of the clinical outcomes from cryptococcal meningitis following treatment induction with 800 mg oral fluconazole in Blantyre, Malawi.
by: Camilla Rothe, et al.
Published: (2013-01-01) -
Pharmacokinetics of consecutive oral moxifloxacin (400 mg/day) in patients with respiratory tract infection
by: Fumitaka Ito, et al.
Published: (2016-02-01)